Outlook Therapeutics, Inc. Common Stock (OTLK) Stock Price
OTLKStock
$0.49−63.57%52W
Market Cap$118.85M
P/E—
PEG Ratio—
Div yield—
Beta0.65
OTLK Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)83.06%
Price vs S&P 500 (4W)-27.54%
VGM Score22.79
OTLK Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.07 | -$0.09 | -20.00%(-$0.02) | |
| Q1 2026 | -$0.12 | -$0.17 | -43.33%(-$0.05) | |
| Q4 2025 | -$0.17 | -$0.22 | -26.93%(-$0.05) | |
| Q3 2025 | -$0.25 | -$0.29 | -17.17%(-$0.04) | |
| Q2 2025 | -$0.39 | -$0.44 | -12.82%(-$0.05) |
OTLK Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
3.90
3.90
3.90
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
OTLKOutlook Therapeutics, Inc. Common Stock | D | F | D | 384.0x | — | — | — | $0.49 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab-gamma), a monoclonal antibody for ophthalmic diseases. LYTENAVA has received marketing approval in the European Union and United Kingdom for wet age-related macular degeneration treatment. The company is pursuing additional indications for its lead therapy as a first-line anti-VEGF option.